Clinical, epidemiological, and mycological features of patients with candidemia : Experience in two tertiary referral centers in Iran
Copyright: © 2021, Published by Mazandaran University of Medical Sciences on behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center..
Background and Purpose: Candidemia is a major cause of morbidity and mortality among patients receiving immunosuppressive therapy and those hospitalized with serious underlying diseases. Here, we investigated the epidemiological, clinical, and mycological features of candidemia in Tehran, Iran.
Materials and Methods: A prospective observational study of all patients diagnosed with candidemia was performed at two referral teaching hospitals in Tehran, Iran, from February to December 2018. Demographic characteristics, underlying diseases, risk factors, clinical symptoms, and laboratory analyses of candidemic patients with positive culture were mined. Candida isolates were molecularly identified by sequencing of the internal transcribed spacer region (ITS1-5.8S-ITS2). The antifungal susceptibility testing for fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, caspofungin, micafungin, and anidulafungin against the isolates was performed using CLSI broth microdilution reference method (M27-A3).
Results: A total of 89 episodes were identified, with an incidence of 2.1 episodes/1000 admissions. The common underling disease were malignancy (46%), renal failure/dialysis (44%), and hypertension (40%). The overall crude mortality was 47%. C. albicans (44%) was the most frequent causative agent, followed by C. glabrata (21%), C. parapsilosis complex (15%), C. tropicalis (11%), and C. lusitaniae (3.5%). All the isolates were susceptible to amphotericin B. The activity of all four azoles was low against non-albicans Candida species, especially C. tropicalis.
Conclusion: The increase in non-albicans Candida species with reduced susceptibility to antifungal drugs might be alarming in high-risk patients. Therefore, accurate knowledge of predisposing factors and epidemiological patterns in candidemia are effective steps for managing and decreasing the mortality rate in candidemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Current medical mycology - 8(2022), 3 vom: 10. Sept., Seite 9-17 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kord, Mohammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal susceptibility |
|---|
| Anmerkungen: |
Date Revised 15.04.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18502/cmm.8.3.11207 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355559110 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355559110 | ||
| 003 | DE-627 | ||
| 005 | 20231226064614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18502/cmm.8.3.11207 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355559110 | ||
| 035 | |a (NLM)37051552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kord, Mohammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical, epidemiological, and mycological features of patients with candidemia |b Experience in two tertiary referral centers in Iran |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2021, Published by Mazandaran University of Medical Sciences on behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center. | ||
| 520 | |a Background and Purpose: Candidemia is a major cause of morbidity and mortality among patients receiving immunosuppressive therapy and those hospitalized with serious underlying diseases. Here, we investigated the epidemiological, clinical, and mycological features of candidemia in Tehran, Iran | ||
| 520 | |a Materials and Methods: A prospective observational study of all patients diagnosed with candidemia was performed at two referral teaching hospitals in Tehran, Iran, from February to December 2018. Demographic characteristics, underlying diseases, risk factors, clinical symptoms, and laboratory analyses of candidemic patients with positive culture were mined. Candida isolates were molecularly identified by sequencing of the internal transcribed spacer region (ITS1-5.8S-ITS2). The antifungal susceptibility testing for fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, caspofungin, micafungin, and anidulafungin against the isolates was performed using CLSI broth microdilution reference method (M27-A3) | ||
| 520 | |a Results: A total of 89 episodes were identified, with an incidence of 2.1 episodes/1000 admissions. The common underling disease were malignancy (46%), renal failure/dialysis (44%), and hypertension (40%). The overall crude mortality was 47%. C. albicans (44%) was the most frequent causative agent, followed by C. glabrata (21%), C. parapsilosis complex (15%), C. tropicalis (11%), and C. lusitaniae (3.5%). All the isolates were susceptible to amphotericin B. The activity of all four azoles was low against non-albicans Candida species, especially C. tropicalis | ||
| 520 | |a Conclusion: The increase in non-albicans Candida species with reduced susceptibility to antifungal drugs might be alarming in high-risk patients. Therefore, accurate knowledge of predisposing factors and epidemiological patterns in candidemia are effective steps for managing and decreasing the mortality rate in candidemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antifungal susceptibility | |
| 650 | 4 | |a Candidemia | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Iran | |
| 650 | 4 | |a Risk factors | |
| 700 | 1 | |a Salehi, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemi, Seyed Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollahi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Alijani, Neda |e verfasserin |4 aut | |
| 700 | 1 | |a Maleki, Ayda |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoudi, Shahram |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadikia, Kazem |e verfasserin |4 aut | |
| 700 | 1 | |a Parsameher, Nasrin |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Abdorahimi, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaie, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemi Fesharaki, Shirin Sadat |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Kiana |e verfasserin |4 aut | |
| 700 | 1 | |a Alcazar-Fuoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Khodavaisy, Sadegh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medical mycology |d 2015 |g 8(2022), 3 vom: 10. Sept., Seite 9-17 |w (DE-627)NLM273575279 |x 2423-3439 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:3 |g day:10 |g month:09 |g pages:9-17 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18502/cmm.8.3.11207 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 3 |b 10 |c 09 |h 9-17 | ||